All News
#ACR23 Abstr#2270 What are the causes of discordance btw #SLE patients and physicians pertaining to disease activity? Survey data from Global COVAD: 45% rate of discordance! Could be related to fatigue levels, pain, poor mental being & impaired physical function @RheumNow https://t.co/kVzGRJm2R8
Md Yuzaiful Md Yusof ( View Tweet)
Great research by @andreafava on urinary biomarkers for lupus nephritis A#0850 #ACR23
IL-17 and other biomarkers can predict renal fxn loss - better than proteinuria!
Article on @RheumNow https://t.co/DeiWFKzNxC
Eric Dein ( View Tweet)
Vasculitis patients associated with increased pregnancy risks
Large study of >600 pregnancies in >500 pts
Vasculitis pts higher frequency of spontaneous abortion, elective termination, ectopic and molar pregnancy, preterm delivery
12% pre-eclampsia
@RheumNow #ACR23 Abs#2425 https://t.co/Nqa77nxSFu
Robert B Chao, MD ( View Tweet)
Pregnancy outcome in Vasculitis - Claim database study
A#2425 #ACR23 @RheumNow
665 vasculitis pts, LVV 60, MV 160, SVV 217, variable 250
Incr risk of preterm delivery, particularly medically-ind deliv, esp Small vessel vasc (5x risk med-induced)
Higer risk pre-eclampsia/eclampsia https://t.co/bWMyY5oqNK
Eric Dein ( View Tweet)
Who knew @FDA_Drug_Info presented #ACR23 posters?! I thought they just issue statements if there was information to be shared! Abst#1822 Bari and Toci use during the pandemic for #COVID19 did not show new safety signals. 1 case HBV reactivation with bari @RheumNow https://t.co/zd7TELsV2j
TheDaoIndex KDAO2011 ( View Tweet)
International collaborative has discussed early referrals for PMR - this is what they’re recommending
Better plans to get the right patients into rheumatologists is a big part of helping #MakeRheumForPMR
ABST2395 #ACR23 @RheumNow https://t.co/Kea07IGxhG
David Liew drdavidliew ( View Tweet)
Antifibrotics in RA-ILD @Juge_P_A Discontinuation in 46% (Mainly GI). Improved FVC trajectory - almost stops decline. Abstr#2479 #ACR23 #ACRbest @RheumNow https://t.co/nZW6TVKefL https://t.co/5BX3PhFhOK
Richard Conway ( View Tweet)
Rashes in Rheumatology at #ACR23
Name the rash? @Rheumnow https://t.co/7CNqOESctW
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR23 Abstr#2334 Can we achieve #SLE DORIS remission with current therapy? Post-hoc analyses of 3 x RCTs + LTE over 4 years showed anifrolumab therapy was associated with more frequent and sustained remission vs PBO during the 4-year period. Good for long-term outcomes @RheumNow https://t.co/eq02yChTZr
Md Yuzaiful Md Yusof ( View Tweet)
Rashes in Rheumatology at #ACR23
Name the rash? @Rheumnow https://t.co/uFjXEOHczZ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dysautonomia & joint hypermobility/hEDS - we all know that patients often have both, but what groups of symptoms cluster for patients?
This French study showed three main groups - need to look at treatment strategies for each group individually
#ACR23 ABST1838 @RheumNow https://t.co/UDepsudpXx
David Liew drdavidliew ( View Tweet)
TM83 #ACR23 @RheumNow
45yo M b/l sacroiliitis, Rx MTX -> ADA -> MTX + Tofa. No improv
Low Ca, & Phos, ALP 239. Nml Vit D, High PTH.
DEXA: Osteoporosis
FGF23 high
PET/CT showed soft tissue density in nasal septum, few cortical breaks
Dx: oncogenic osteomalacia 2/2 malignancy https://t.co/EOcYNtovBy
Eric Dein ( View Tweet)
Review of rashes in SLE at #ACR23 by Dr. Katherine Shaw, MD
⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment.
@RheumNow https://t.co/u7dwDe9kbt
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Real-world tolerability of anti-fibrotics (nintedanib, pirfenidone) in RA-ILD @BrighamWomens:
patients do drop out because of AEs, but a decent chunk are okay and do get modest benefit
@Juge_P_A @jeffsparks #ACR23 ABST2479 @RheumNow https://t.co/BpM14eizmF
David Liew drdavidliew ( View Tweet)
⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment.
🚩Phase II trial of Iberdomide in SLE:
➡️ not associated w/ statistically significant improvement in CLASI-A when including ALL CLE subtypes… https://t.co/LHNqKMALzU https://t.co/K73sXjFTHM
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
TM84 #ACR23 @RheumNow
49F MS on RTX, severe arthralgias/wt loss, BMI 18. Spontaneous peritonitis, aseptic discitis/osteo, distal radius lucency, hyperammonemia, hypogammaglobulinemia w 1 yr arthritis
Dx: Mycoplasma: ureaplasma urealyticam on culture, PCR improved https://t.co/jM0sARLZS7
Eric Dein ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Watch: Correlation Between Patient and Physicians Assessments in PsA Save
Dr. Antoni Chan interviews Dr. Avin Maroof at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/syG4Ry08vF https://t.co/6g9SpISSIt
Dr. John Cush RheumNow ( View Tweet)
Merging field moving forward - cardio-rheumatology collaboration imp!
Calcium scores in older patients with #RA may be the one take away! Very important to risk predict and mitigate CV events .
Ofcourse history taking still remains key! session 14T118 #ACR23 @RheumNow https://t.co/xoldFlA8EW
Bella Mehta bella_mehta ( View Tweet)
#ACR23 Late-Breaking Abstr#L13 CAR-T is in CT but not RCT yet. Preliminary results from open label (N=3 #SLE of YTB323 (rapcabtagene autocel CD19 directed with preserved T cell stemness) showed favourable CAR T expansion, B cell depletion, early efficacy & safety @RheumNow https://t.co/UQUOfDbFJe
Md Yuzaiful Md Yusof ( View Tweet)